Stock DNA
Pharmaceuticals & Biotechnology
JPY 134,027 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.18
-6.46%
3.80
Revenue and Profits:
Net Sales:
6,932 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1,077 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.06%
0%
-9.06%
6 Months
-34.98%
0%
-34.98%
1 Year
-26.4%
0%
-26.4%
2 Years
-24.64%
0%
-24.64%
3 Years
69.29%
0%
69.29%
4 Years
68.56%
0%
68.56%
5 Years
30.22%
0%
30.22%
GNI Group Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
23.51%
EBIT Growth (5y)
-204.12%
EBIT to Interest (avg)
3.09
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
0.67
Tax Ratio
8.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
13.87%
ROE (avg)
8.25%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.18
EV to EBIT
-113.68
EV to EBITDA
-274.17
EV to Capital Employed
6.89
EV to Sales
8.99
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-6.06%
ROE (Latest)
-7.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
6,931.70
5,320.70
30.28%
Operating Profit (PBDIT) excl Other Income
19.60
-236.20
108.30%
Interest
366.00
428.80
-14.65%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1,076.50
-1,266.20
14.98%
Operating Profit Margin (Excl OI)
-34.90%
-97.10%
6.22%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 30.28% vs -17.12% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 14.98% vs -105.12% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
23,611.70
26,010.60
-9.22%
Operating Profit (PBDIT) excl Other Income
436.70
5,189.00
-91.58%
Interest
1,452.40
1,250.70
16.13%
Exceptional Items
-148.30
8,698.20
-101.70%
Consolidate Net Profit
-9.60
9,504.10
-100.10%
Operating Profit Margin (Excl OI)
-23.10%
176.10%
-19.92%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -9.22% vs 49.32% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -100.10% vs 1,194.56% in Dec 2023
About GNI Group Ltd. 
GNI Group Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






